Bernstein SocGen cuts Alnylam stock price target on Amvuttra focus By Investing.com

Bernstein SocGen trimmed its price target on Alnylam to $448 from $451 while keeping an Outperform rating, slightly below the current $313.79 share price context but still constructive. The firm models Amvuttra sales at $842 million versus $840 million consensus and EPS of $1.31, about 9% below Street estimates, while citing TTR as the main investor debate. Pipeline readouts through year-end 2026, including Phase 2 HHT, Phase 1 Huntington's, and Phase 1 ALK7, are expected in the second half of the year.

Analysis

The key market setup is not the modest price-target reset; it is the widening gap between a durable commercial asset and a pipeline that is being underwritten as if it were optional. That creates a favorable asymmetry for longs into print: if TTR revenue merely holds near the low end of guidance, the stock can re-rate on execution confidence even without any new clinical catalyst. The market is still treating pipeline spend as a near-term drag rather than a portfolio option with multiple shots on goal over the next 12-24 months.

The bigger second-order effect is on competitive positioning in rare disease and cardiometabolic RNA therapeutics. A successful ongoing launch in ATTR gives Alnylam a reinforcement loop: better payer leverage, more physician confidence, and more credibility for the rest of the franchise, which raises the bar for later entrants that will need to displace an already familiar regimen rather than a theoretical standard of care. That same dynamic can pressure adjacent names with similar launch narratives if their data cadence slips even modestly.

Contrarian take: the selloff may have already priced in a “miss” scenario on spend and near-term EPS, but not a high-probability base case where revenue holds and pipeline readouts extend the runway. The real risk is timing, not thesis: a quarter or two of softer margins could keep the stock range-bound until investors see whether the second-half readouts create a credible multi-asset story. If those data are merely incremental, the multiple stays capped; if one readout is clearly de-risking, the stock can recover quickly because expectations are already depressed.

For MS, the read-through is more neutral than directional: the market is rewarding the broader tape, but there is no company-specific impetus here. Any benefit is indirect via improving risk appetite for growth and healthcare names, not from fundamental linkage.

Key Decisions for Investors

• Add ALNY on pullbacks toward the low-300s over the next 1-2 weeks; use a 6-9 month horizon and target a re-rating toward the mid- to high-300s if TTR and launch metrics remain intact.
• Buy ALNY call spreads into the next earnings print: 6-10% upside strike width, expiring 2-4 months out, to express the view that execution stability matters more than modest estimate noise.
• Pair trade: long ALNY / short a later-stage RNA or rare-disease peer with a more fragile commercial ramp over the next quarter; the relative trade favors the incumbent with the clearest revenue base and multiple pipeline catalysts.
• If ALNY gaps lower on earnings purely from margin/R&D noise but revenue is within range, buy the dip aggressively; that would likely be a 1-3 day dislocation rather than a thesis break.
• Trim or avoid outright short exposure until after the second-half pipeline readouts; the catalyst path over 6-18 months is skewed toward positive surprise, while downside is mostly execution timing.